Symbiotec Pharmalab Ltd (SYMBIOTEC) — Announcement | 1 September 2026
Symbiotec Pharmalab disclosed that its key managerial personnel have been authorized to assess materiality and disclose events under SEBI's Regulation 30(5), effective September 1, 2026. This formalizes internal reporting protocols for material information, enhancing governance transparency for investors.
About Symbiotec Pharmalab Ltd (SYMBIOTEC)
Healthcare · Pharmaceuticals · Listed on BSE
📡 Get AI alerts when SYMBIOTEC files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track SYMBIOTEC — Free💡 Ask AI about this filing
📊 More SYMBIOTEC filings
No other filings yet.
🔥 Also filed on 1 September 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when SYMBIOTEC files new disclosures
Track SYMBIOTEC filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track SYMBIOTEC — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd